Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
67%(6 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
2
17%
Ph phase_3
8
67%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
8(72.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(3)

Detailed Status

Completed9
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
81.8%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (9.1%)
Phase 22 (18.2%)
Phase 38 (72.7%)

Trials by Status

completed975%
terminated217%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227
completedphase_3

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
completed

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

NCT04170309
terminatedphase_1

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

NCT02527681
completedphase_3

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05856227Phase 3

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Completed
NCT03138733Phase 3

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Completed
NCT04170309

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Completed
NCT02527681Phase 1

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Terminated
NCT03137173Phase 3

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Completed
NCT03439124Phase 3

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Completed
NCT03317093Phase 2

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

Completed
NCT00505258Phase 2

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

Withdrawn
NCT00326287Phase 3

Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

Completed
NCT00529282Phase 3

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Terminated
NCT00228982Phase 3

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Completed
NCT00210899Phase 3

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12